Moderna (MEX:MRNA) Future 3-5Y EPS without NRI Growth Rate : 22.36 (As of Oct. 10, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Moderna Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Moderna's Future 3-5Y EPS without NRI Growth Rate is 22.36.

Competitive Comparison of Moderna's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Moderna's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Moderna's Future 3-5Y EPS without NRI Growth Rate falls into.

Moderna (MEX:MRNA) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Moderna Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Moderna's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (MEX:MRNA) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru 1MRNA:Italy 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil 0QF:Bulgaria MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.